Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.33 |
| ▸ | PPIA | P62937 | 2/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1536746 | 0.90 | MEN1 (0.37) | MEN1MAPK1KMT2ADGAT1CHRM1 | |
| SCHEMBL16244146 | 0.85 | MEN1 (0.34) | MEN1MAPK1KMT2ADGAT1CHRM1 | |
| SCHEMBL1536186 | 0.84 | MEN1 (0.40) | MEN1MAPK1KMT2ADGAT1CTSL | |
| SCHEMBL30562194 | 0.84 | MEN1 (0.40) | MEN1MAPK1KMT2ADGAT1CTSL | |
| SCHEMBL16118624 | 0.84 | MEN1 (0.40) | MEN1MAPK1KMT2ADGAT1HSD11B1 | |
| SCHEMBL22874207 | 0.84 | CACNA1H (0.38) | MEN1MAPK1KMT2ACHRM1CTSL | |
| SCHEMBL17213668 | 0.83 | CHRM1 (0.41) | CHRM1HSD11B1HSD11B2 | |
| SCHEMBL23879650 | 0.83 | HSD11B1 (0.47) | MEN1MAPK1KMT2ADGAT1CTSL | |
| SCHEMBL29602101 | 0.83 | MEN1 (0.42) | MEN1MAPK1KMT2ADGAT1CTSL | |
| SCHEMBL20575845 | 0.82 | MEN1 (0.41) | MEN1MAPK1KMT2ADGAT1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015352-A1 | METHYLTRANSFERASE INHIBITOR AND USE THEREOF | CYTOSINLAB THERAPEUTICS CO LTD (CN) | 2026-01-15 | — | — | US | disclosed |
| EP-4572755-A2 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20250195518-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2025-06-19 | — | — | US | disclosed |
| EP-4488271-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2025-01-08 | — | — | EP | disclosed |
| US-20240173419-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| CN-112778183-B | Nitrogen-containing ring derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-05-10 | — | — | CN | disclosed |
| WO-2024039901-A2 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| WO-2024012461-A1 | METHYLTRANSFERASE INHIBITOR AND USE THEREOF | 上海赛岚生物科技有限公司 | 2024-01-18 | — | — | WO | disclosed |
| WO-2023163140-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | 日本たばこ産業株式会社 | 2023-08-31 | — | — | WO | disclosed |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| WO-2011068881-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011068881-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195518-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | HPGDS, PTGIS, HPGD | MEN1 2939/4885MAPK1 2015/4885KMT2A 3715/4885 |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | MEN1 3090/4885MAPK1 2860/4885KMT2A 3548/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | MEN1 3090/4885MAPK1 2860/4885KMT2A 3548/4885 |
| US-20240173419-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | MEN1 2032/4885MAPK1 1869/4885KMT2A 290/4885 |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | MEN1 3478/4885MAPK1 927/4885KMT2A 4497/4885 |
| US-20260015352-A1 | METHYLTRANSFERASE INHIBITOR AND USE THEREOF | EZH2, DOT1L, EHMT1 | MEN1 2466/4885MAPK1 1297/4885KMT2A 16/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | MEN1 3090/4885MAPK1 2860/4885KMT2A 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.